Results: One thousand four hundred and forty-eight S. aureus and 1214 CoNS were collected. The overall prevalence of methicillin resistance was 42% (with 6% annual fluctuation) for S. aureus and 67% (range 54% to 80%) for CoNS. Resistance to aminoglycosides, macrolides, quinolones and tetracyclines was strongly associated with methicillin resistance in both species groups. Many (20.8%) CoNS and three (0.2%) S. aureus isolates were non-susceptible to teicoplanin, but there was no vancomycin non-susceptibility found in S. aureus and only one vancomycin-intermediate CoNS isolate. There was little evidence of susceptibility trends over time for any antibiotic, with the surveillance period preceding the recent fall in methicillin-resistant S. aureus (MRSA) prevalence indicated by the mandatory surveillance of MRSA bacteraemia in England. The newer antibiotics, ceftobiprole, daptomycin, linezolid, telavancin and tigecycline, all had excellent activity against staphylococci.
Introduction
Staphylococcus aureus is the bacterial pathogen of which the British public are most aware, owing to the prolific media coverage of methicillin-resistant S. aureus (MRSA). MRSA is not only a UK problem; internationally, it poses a very substantial heathcare threat, and in some countries, including the UK, epidemic MRSA strains have become endemic in many hospitals. 1 -6 S. aureus was the most commonly isolated pathogen from bacteraemias in the UK in the first few years of this century but has now been overtaken by Escherichia coli. On admission to hospital in the UK, one in three patients is already colonized with S. aureus; a significant fraction of care-home residents and readmissions may already carry MRSA.
The British Society for Antimicrobial Chemotherapy (BSAC) Bacteraemia Surveillance Programme aims to provide highquality microbiological data, with molecular investigation of unusual strains. In this report, the data for staphylococci collected between 2001 and 2006 are reviewed and compared with the findings of other surveillance programmes, including the UK Health Protection Agency (HPA) voluntary bacteraemia surveillance, 10 the national mandatory system for monitoring of MRSA bacteraemias and the European Antimicrobial Resistance Surveillance System (EARSS). 2 These are more wide-ranging than the BSAC programme, but do not collect bacteria for central investigation, with the exception of UK EARSS MRSA and pneumococci isolates, which do have their results centrally verified.
Materials and methods
The collection, testing and statistical methods used in the BSAC Bacteraemia Programme are detailed elsewhere in this Supplement. 11 Until 2005/06, resistance to methicillin was inferred from oxacillin resistance, with cefoxitin also tested in 2004/05 only. Subsequently, mecA and also mupA alleles were sought in S. aureus and CoNS from 2005 and 2006, respectively, by PCR, using methods detailed previously. 12, 13 Isolates were deemed to be methicillin-resistant if mecA was detected, regardless of the results of phenotypic testing.
Results

Sources of S. aureus and MRSA
One thousand four hundred and forty-eight S. aureus isolates were submitted from 2001 to 2006. Table 1 shows the age distribution of the patients from whom the isolates were obtained. Sixty percent of these were from patients over 60 years of age, with a male:female ratio of 3:2. The majority (61%) of the isolates were from patients admitted to hospital for .48 h, but 37% of them were from out/community patients (5.7%) or those admitted for 48 h (31%). The top three specialties associated with S. aureus were general medicine, surgery and nephrology, accounting for 25%, 17% and 14% of submissions, respectively.
The origin of the S. aureus bacteraemias remained unknown in 33% of cases, while lines, skin or soft tissue and the respiratory tract comprised the three highest-ranked known sources, accounting for 25%, 16% and 9% of the cases, respectively. Of the 1448 isolates, 613 (42%) were MRSA. The prevalence varied between years from 36% to 48% without any discernible year-on-year trend in proportion, at least until 2006. The proportion of MRSA increased with age, rising to 51% for patients 70 years of age, independent of the patient's sex. Among patients who had been admitted to hospital for .48 h before their S. aureus bacteraemia was first identified, 50.5% had MRSA, compared with 28.4% among those whose bacteraemia was identified within 48 h of admission or who were from the community or outpatients. Many of these latter patients may have had recent hospital contact and the data do not challenge the view that MRSA largely remains a hospital-acquired pathogen in the UK and Ireland. The prevalence of MRSA was highest in intensive care units (ICUs) (63.5%), care of the elderly (58%) and surgery (50.8%).
Antibiotic resistance and trends in S. aureus
Antibiotic resistance in S. aureus is discussed here in terms of methicillin-susceptible S. aureus (MSSA) and MRSA, as multiresistance (resistance to two or more classes of antibiotic) was strongly associated with methicillin resistance. Table 2 summarizes the susceptibilities of MSSA isolates. Non-susceptibility rates were highest for penicillin, erythromycin and cefoxitin, at 82%, 28% and 19% respectively. Cefoxitin 'resistance' in 24 MSSA is perplexing as the trait is viewed as an indicator for mecA-mediated resistance.
14 These isolates were all oxacillin-susceptible (MIC 2 mg/L with a mode of 0.5 mg/L) and were confirmed mecA-negative by PCR. They all required cefoxitin MICs of 8 mg/L, which is one doubling dilution above both the breakpoint and the modal cefoxitin MIC for MSSA based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) MIC distribution. 15 In contrast, cefoxitin MICs for genuine MRSA isolates ranged from 16 to .128 mg/L, meaning that discrimination between MSSA and MRSA remained good, but with a breakpoint of 16 mg/L rather than 4 mg/L.
Although erythromycin resistance was observed frequently in MSSA, the levels of resistance were quite different from those in MRSA; erythromycin resistance in MRSA was often high, with 93% of the resistant isolates having MICs 128 mg/L. Among MSSA, only 25% of the resistant isolates had MICs at this level, whereas 48% required MICs of 1 mg/L, corresponding to only one dilution above the susceptible breakpoint.
Methicillin resistance (Table 3 ) was strongly associated with other resistances in S. aureus. For several drugs, the difference in the proportion of resistance between MRSA and MSSA was highly significant (P , 0.00001), e.g. 95.9% of MRSA were resistant to ciprofloxacin, whereas for MSSA this was only 9.1%. The pattern of high-level ciprofloxacin resistance is typical of the EMRSA-15 and -16 clones that dominate MRSA in the UK. Curiously, one MRSA isolate was susceptible to oxacillin; this isolate poorly expressed the mecA gene in vitro. The only established drugs where there was no significantly greater prevalence of non-susceptibility in MRSA than MSSA were fusidic acid, minocycline and tetracycline. These isolates should be considered to require less than or equal to or more than or equal to the listed MIC dependent upon whether they are at the bottom or top of the MIC range.
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Hospital acquisition of infection, specialty ( particularly ICU) and age group were significant independent predictors of S. aureus bacteraemia being caused by MRSA, generally with its associated resistances to other antimicrobials. In addition, age group was a significant predictor of ciprofloxacin resistance in MSSA and MRSA separately. In MSSA, the prevalence of ciprofloxacin resistance increased with age, being 3.9%, 9.5%, 6.3% and 16.4% in age groups 0 -19, 20 -59, 60 -79 and 80 years, respectively. In contrast, the prevalence of ciprofloxacin resistance in MRSA was .90% in all age groups over the age of 4 years (mean 96.9%, n ¼ 604), but was strikingly lower in children up to the age of 4 years (17%, n ¼ 6). This may reflect the dominance of the same few MRSA lineages across most age groups while different clones tend to infect the very young. There are reports of ciprofloxacin-susceptible 'paediatric' MRSA clones in France, Japan, Portugal and Brazil, but as yet no occurrence of this clone in the UK paediatric patients has been reported, although it has been found in the adult population, and ciprofloxacin-susceptible MRSA strains have been reported in UK paediatric patients. 5,16 -18 Seven S. aureus isolates in 2006 carried the mupA gene, which confers high-level resistance to mupirocin. All of these isolates except one were also mecA-positive. There was no nonsusceptibility to linezolid or vancomycin, and only three teicoplanin non-susceptible isolates (one MSSA and two MRSA).
Among the newest antibiotics with anti-S. aureus activity, ceftobiprole, daptomycin, tigecycline and telavancin all performed well. EUCAST has assigned MIC breakpoints for tigecycline (S 0.5; R . 0.5 mg/L) and daptomycin (S 1; R . 1 mg/L). Only two isolates were resistant to tigecycline on these criteria, both with borderline MICs of 1 mg/L while no resistance was found to daptomycin. Ceftobiprole MICs for staphylococci were all 4 mg/L, ranging from 0.25 to 4 mg/L (mode 2 mg/L) for MRSA and 0.25 to 1 mg/L (mode 0.5 mg/L) for MSSA. Telavancin MICs for both MRSA and MSSA were all in the range of 0.12 -0.5 mg/L. (Table 4 ). The 2001 -05 collections (n ¼ 1011) were identified to species level as follows: Staphylococcus epidermidis (n ¼ 615, 60.8%), Staphylococcus haemolyticus (n ¼ 123, 12.2%), Staphylococcus hominis (n ¼ 107, 10.6%), unspeciated Staphylococcus (n ¼ 73, 7.2%), Staphylococcus capitis (n ¼ 72, 7.1%), Staphylococcus warneri (n ¼ 12, 1.2%) and Staphylococcus saprophyticus (n ¼ 9, 0.9%). Species identification was discontinued in 2006. The largest number of isolates (19.4%, n ¼ 236) was from patients aged 60-69 and the male:female split was 56%:42%. Sixty-eight percent of the isolates were from patients who had been admitted to hospital for .48 h, the remainder being from community/outpatients (7.3%) or those admitted for 48 h (19.3%). The largest number (30%, n ¼ 365) of isolates was from haematology/oncology patients followed by nephrology (14%, n ¼ 67) and ICU (12% n ¼ 146). Intravascular lines accounted for 62% of the cases, with a further 27% noted as being of unknown source. Tables 5 and 6 summarize the antibiotic susceptibilities and MIC ranges for the CoNS. Species was significantly related to resistance even when other factors, such as source of bacteraemia, age group or referring specialty, were included in the multiple logistic regression model. S. haemolyticus was more resistant than the other species with 84% of the isolates nonsusceptible to three or more of ciprofloxacin, erythromycin, gentamicin, oxacillin, teicoplanin and tetracycline. This compared with S. epidermidis where 70% of the isolates were nonsusceptible to three or more of these antibiotics.
Distribution of CoNS in bacteraemia
Antibiotic resistance and trends in CoNS
There were no smooth year-on-year resistance trends for any antibiotic, but there was some evidence of fluctuation in nonsusceptibility between years for oxacillin, erythromycin, clindamycin, teicoplanin, tetracycline and tigecycline. The year-on-year variation for oxacillin, teicoplanin and tetracycline could be due to experimental variation as the breakpoints for these antibiotics lie on, or close to, the MICs of many susceptible isolates, meaning that 2-fold variation in MIC can change the susceptibility category. Apparent differences seen in tigecycline MICs between years were almost wholly due to high MICs seen in 2002; these were probably due to incorrect handling of tigecycline which is susceptible to oxidization during in vitro susceptibility testing. 19 The 14 The newer antibiotics, ceftobiprole, daptomycin, tigecycline and telavancin were almost universally active against CoNS, with patterns similar to those for S. aureus. For instance, the Some data fields incomplete, and hence percentages do not always total 100%.
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ceftobiprole MIC ranges were 0.015 -4 mg/L (mode 0.5 mg/L) for MSCoNS and 0.008 -4 mg/L (mode 1 mg/L) for MRCoNS.
Discussion
Owing to its high profile, MRSA is now the subject of multiple surveillance programmes in the UK, all concentrating on isolates from bacteraemia. Aside from the BSAC surveillance programme detailed in this report, these include the Department of Health's mandatory MRSA reporting scheme launched in April 2001 20 and coordinated by the HPA, the HPA's continued voluntary reporting under LabBase 10 and the EARSS launched in 1999. 2 These programmes are independent but overlapping and complementary, and Table 7 compares the UK and Irish MRSA prevalence data from the four surveillance programmes. All four studies reported MRSA prevalence rates within the range 36% to 48% throughout the surveillance period. Within the UK, the two sentinel surveys, BSAC and EARSS, both showed higher prevalence of MRSA than either the mandatory reporting or the LabBase programme, which rely on routine laboratory data, perhaps because larger centres, often with more MRSA, are more willing and, owing to higher staffing levels, better able to participate in sentinel surveillance. All studies except the BSAC saw some reduction in the proportion of Since April 2006, the mandatory surveillance for England has collected patient characteristics and case information, obtaining age and sex data for 98% of 6264 patients with MRSA bacteraemias from April 2006 to March 2007. As in the BSAC data set, the incidence of MRSA increased with age and there were more cases in men than women. This 'enhanced' mandatory surveillance showed that 65% of the MRSA bacteraemias arose .48 h after admission, agreeing well with the BSAC surveillance which estimated this proportion as 72% over the entire programme and 71% for 2006. The two specialties with the top ranking number for MRSA bacteraemia cases according to the enhanced mandatory surveillance were general medicine (1436) and general surgery (770), and these were also the top-ranking specialties in the BSAC surveillance.
The UK's MRSA problem is dominated by two lineages, EMRSA-15 and -16, both of which are typically resistant to quinolones and macrolides, with EMRSA-16 sometimes also being resistant to gentamicin. 1 The BSAC surveillance did not show any trend among MRSA in relation to resistance in these agents and neither is currently reported by the mandatory surveillance or EARSS. However, non-susceptibility to erythromycin and gentamicin reduced significantly over time in the LabBase MRSA data, falling from 84.9% to 78.6% (P , 0.0001) and from 10.9% to 6.8% (P , 0.0001) respectively. The only antibacterial for which there was a significant (P , 0.0001) increase in non-susceptibility in the LabBase data for MRSA was trimethoprim, with non-susceptibility increasing from 27.3% to 31.9%. It is uncertain whether these changes reflect gradual loss or gain of resistance by EMRSA-15 or -16 or the gradual penetration of other clones. Table 8 compares the prevalence of resistance among S. aureus and CoNS isolates from the BSAC and LabBase programmes. In general, there was a good agreement between the estimated non-susceptible prevalence levels determined by these two surveillance programmes for both S. aureus and CoNS. However, there were a number of key discrepancies between the two studies, some of these almost certainly being laboratory routine testing errors. The LabBase data indicated ,0.3% nonsusceptibility to vancomycin among MRSA isolates, whereas the BSAC study found all MRSA susceptible. Since the reference laboratory requests that all vancomycin non-susceptible S. aureus isolates are submitted for confirmatory testing and none have yet been confirmed, we would treat the LabBase proportion with suspicion. In the case of teicoplanin, non-susceptibility was consistently higher in the BSAC study, particularly among CoNS. This discrepancy was most probably due to the underestimation of non-susceptibility by routine disc testing, where the zone diameter for this large, poorly diffusing antibiotic is poorly related to the MIC and disc testing therefore not recommended by BSAC. 14, 23 Other differences between the two studies, for example, in estimated susceptibility to clindamycin in S. aureus, trimethoprim in MSSA, erythromycin in MSCoNS and MSSA and tetracycline in CoNS, are not so easily explained but are probably caused by differences in sampling strategy and susceptibility determination methods. The BSAC and LabBase surveillance both confirmed that methicillin resistance was more prevalent among CoNS than among S. aureus, as is widely perceived. Nevertheless, the clinical significance of MRCoNS is mitigated somewhat by low pathogenicity. However, it has been suggested that CoNS may act as a reservoir for resistance genes that can disseminate into S. aureus.
24 Therefore, continued surveillance of CoNS is justified. Methicillin-and multiresistant staphylococci are not just a UK problem but a worldwide one, as illustrated by the EARSS 2006 data which show that 12/27 participating countries had MRSA prevalence levels of 25% to 50% in bacteraemia with Romania having .50%, and only 7 had MRSA rates 5%. In the USA, the Centers for Disease Control Active Bacterial Core surveillance system operates similarly to the UK LabBase system and, in 2004 -05, estimated the percentage of MRSA in the USA at 77% for hospital-associated S. aureus bacteraemia and 65% for community-associated bacteraemia. The majority of the cases were caused by the USA100 or USA300 strains, the former largely being hospital-acquired and the latter, while classically considered a community strain, is also moving into hospitals. 3 In the UK, we have yet to see a community MRSA strain establish itself widely as a hospital-acquired pathogen, though the risk must be taken seriously. With its multiple surveillance systems tracking MRSA rates, any emergence of new epidemic clones should be rapidly detected in the UK, allowing control strategies to be brought to bear.
Treatment options for methicillin-resistant staphylococci
The multiresistant nature of many methicillin-resistant staphylococci leads to a significant therapeutic problem, particularly in serious infections such as bacteraemia. Standard first-line treatment of MRSA bacteraemia is with glycopeptides, often in combination with rifampicin or fusidic acid. However, there is growing support for the view that vancomycin therapy is less effective for infections caused by isolates with vancomycin MICs of 2 mg/L. 25 -28 In this study, 27.2% of MRSA isolates required MICs of 2 mg/L. This cannot be compared with other surveillance data, as the BSAC is the only programme to report MICs. Of the newer antibiotics tested here, ceftobiprole, daptomycin, linezolid, telavancin and tigecycline all had excellent activity versus the staphylococci, with no resistance or, in the case of tigecycline, no convincing resistance (some MICs just above the breakpoint). These agents considerably increase the number of therapeutic options available to treat methicillinresistant staphylococci and could help combat the over-reliance on vancomycin and teicoplanin.
In conclusion, multiresistant S. aureus and CoNS remain abundant in the UK and Ireland, but there are hopeful signs: first in the diminished incidence of MRSA seen in the mandatory surveillance data (though not yet in the BSAC surveillance), and secondly in that there are a growing number of treatment options available for infection caused by these bacteria. The newer agents tested here had excellent in vitro antimicrobial activity and may well prove to be effective alternatives to glycopeptides. So far, however, only daptomycin has been evaluated clinically in bacteraemia. 29, 30 publications from the Project, some of which may include parts of the information presented here.
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